A241 KIWIFRUIT AND KIWIFRUIT EXTRACTS FOR TREATMENT OF CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. (21st February 2022)

• Record Type: Journal Article
• Authors: Eltorki, M; Leong, R; Ratcliffe, E
• Is Part Of: Journal of the Canadian Association of Gastroenterology. Volume 5(2022)Supplement 1
• Page Start: 133
• Page End: 134
• Publication Date: 2022-02-21
• Subjects: Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1093/jcag/gwab049.240
• Languages: English
• ISSNs: 2515-2084

Abstract

Abstract: Aims: This systematic review and meta-analysis aimed to determine the effectiveness of kiwifruit or kiwifruit extracts in thetreatment of constipation. Methods: Electronic databases were searched from inception until January 2021. Eligible studies enrolled participants with functional constipation (FC) or irritable bowel syndrome with constipation (IBS-C) with randomization to receive kiwifruit or kiwifruit extracts vs. any non-kiwifruit control. Standardized meandifference (SMD) or mean difference (MD) with confidence intervals (CI) were determined for the following outcomes: weekly frequency of spontaneous bowel movements (SBM) and Bristol Stool Scale (BSS). GRADE approach was used to rate the certainty of evidence. PROSPERO registration number CRD42020207365. Results: Seven randomized controlled trials including 399 participants (82% female; mean age 42 years [Standard Deviation 14.6]) were included. Compared with placebo, kiwifruit extract might increase weekly frequency of SBM (MD 1.36; 95% CI -0.44 to 3.16) with low certainty evidence. Kiwifruit had an uncertain effecton BSS (SMD 1.54; 95% CI -1.33 to 4.41) with very low certainty evidence. Compared with psyllium, kiwifruitmay increase weekly SBM (MD 1.1; 95% CI -0.02 to 2.04) and may increase BSS (softer stools) (MD 0.63;95% CI 0.01 to 1.25) both with low certainty evidence. Compared to placebo, kiwifruit encapsulated extracts may result in an increase in minor adverse events (Relative Risk 4.58; 95% CI 0.79 to 26.4). Conclusions: Among individuals with constipation, overall low certainty of evidence indicate that kiwifruit may increase SBM when compared to placebo or psyllium. Although overall results are promising, establishing therole of kiwifruit in FC or IBS-C requires large, methodologically rigorous trials. Funding Agencies: None